Abstract: #142 Eradication of HCV Induced by Direct-Acting Antivirals Is Associated with a 79% Reduction in HCC Risk. – George N. Ioannou, et al.
The goal of this large study was to evaluate the risk of hepatocellular carcinoma (HCC) in people diagnosed with HCV who experienced a viral cure (SVR) using DAAs. Further, this research compared the HCC risk for SVRs achieved by DAAs versus interferon-based regimens.
This research used data collected from 62,051 patients who underwent 83,695 antiviral treatment regimens in the Veterans Affairs national healthcare system from 1999-2015. There were 35,873 (57%) interferon-only regimens; 26,178 (43%) DAA ±interferon regimens; 21,644 (35%) DAA-only regimens.
Conclusion: Among all patients, SVR was associated with a 70% reduction in HCC risk. The risk of HCC was highest among patients with cirrhosis who failed treatment. Patients with cirrhosis who had an SVR had the next highest risk of HCC. The lowest risk was among patients without cirrhosis who achieved SVR, followed by those with no cirrhosis who did not have an SVR. Patients with an SVR following DAA treatment had a 79% reduction in HCC risk.
Editorial Comments: This is one of many studies that reported similar findings. The size of this study strongly enforces the notion that curing HCV with DAAs should be initiated early, and offered to everyone with HCV.
To read the entire newsletter, click here